FANCA and cancer: Therefore, it is interesting to investigate whether germline <i>FANCA</i>-mutated relapsed epithelial OC could achieve clinical benefit from the treatment of PARP inhibitor.<h4>Case presentation</h4>A 49-year-old female patient without a family history of cancer was diagnosed with epithelial OC.